ClinicalTrials.gg
CompletedNCT01419717Updated Sep 24, 2019Results posted

Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer

A Phase 3 interventional study of Denosumab in Bone Metastases in Men With Hormone-Refractory Prostate Cancer and Bone Metastases in Subjects With Advanced Breast Cancer, sponsored by Amgen. Completed at 64 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-24.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
129
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This trial will facilitate access to denosumab for adults with advanced cancer who have participated in a denosumab phase 3 study until denosumab is approved and available for sale.

02

Conditions studied

  • Bone Metastases in Men With Hormone-Refractory Prostate Cancer
  • Bone Metastases in Subjects With Advanced Breast Cancer

Keywords

  • cancer
  • bone metastases
  • breast cancer
  • prostate cancer
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 129 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject was previously enrolled in a denosumab phase 3 study and participated in the Open-label Extension portion of that study.
  • Subject or subject's legally acceptable representative has provided .

Exclusion criteria

Exclusion Criteria:

  • Subject is of child bearing potential and planning to become pregnant within 7 months after the end of treatment.
  • Subject is of child bearing potential and is not willing to use, in combination with her partner, two highly effective methods of during treatment and for 7 months after the end of treatment.
  • Subject has known sensitivity to any of the products to be administered during dosing.
  • Subject will not be available for protocol required study visits or procedures, to the best of the subject and investigator's knowledge.
  • Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written and/or to comply with all required study procedures.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    Denosumab

    Participants received 120 milligrams of denosumab injected subcutaneously every 4 weeks until denosumab was approved and available for sale.

    Drug: Denosumab

Interventions

  • Administered by subcutaneous injection every 4 weeks (Q4W)

    Also known as: Xgeva

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. The event does not necessarily have a causal relationship with study treatment. Each AE was graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, where Grade 1 = Mild AE Grade 2 = Moderate AE Grade 3 = Severe AE Grade 4 = Life-threatening or disabling AE Grade 5 = Death related to AE. Treatment-related adverse events (TRAEs) includes events for which the investigator indicated there was a reasonable possibility they may have been caused by investigational product.

    Time frame: From first dose of denosumab in Study 20110113 to end of study; median (minimum, maximum) time on study was 13.93 (0.0, 74.7) months.

Secondary outcomes

  1. Number of Participants With Anti-denosumab Binding Antibodies

    A blood sample was collected at the end of study visit for the measurement of anti-denosumab binding antibodies.

    Time frame: Assessed at end of study; the median (minimum, maximum) time on study for all enrolled participants was 13.9 (0.0, 74.7) months.

07

Results

Posted Sep 9, 2019

Participant flow

This study was conducted at 65 centers in Europe, Latin America, Japan, and South Africa. Participants were enrolled from 22 November 2011 to 27 October 2014.

Participant flow — Overall Study
MilestoneDenosumab
Started129
Received denosumab128
Completed4
Not completed125
Withdrew: Protocol-specified criteria62
Withdrew: Adverse event19
Withdrew: Death17
Withdrew: Withdrawal by subject10
Withdrew: Disease progression9
Withdrew: Other4
Withdrew: Lost to follow-up2
Withdrew: Administrative decision1
Withdrew: Noncompliance1

Outcome measures

PrimaryNumber of Participants With Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. The event does not necessarily have a causal relationship with study treatment. Each AE was graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, where Grade 1 = Mild AE Grade 2 = Moderate AE Grade 3 = Severe AE Grade 4 = Life-threatening or disabling AE Grade 5 = Death related to AE. Treatment-related adverse events (TRAEs) includes events for which the investigator indicated there was a reasonable possibility they may have been caused by investigational product.

Time frame:
From first dose of denosumab in Study 20110113 to end of study; median (minimum, maximum) time on study was 13.93 (0.0, 74.7) months.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsDenosumab
All adverse events98
Serious adverse events45
AE leading to discontinuation of denosumab28
AE leading to discontinuation from study22
Fatal adverse events18
AE grade 3, 4, or 546
Treatment-related adverse event26
Treatment-related serious adverse event10
TRAE leading to discontinuation of denosumab18
TRAE leading to discontinuation from study16
Treatment-related fatal adverse events0
Treatment-related AE grade 3, 4, or 58
SecondaryNumber of Participants With Anti-denosumab Binding Antibodies

A blood sample was collected at the end of study visit for the measurement of anti-denosumab binding antibodies.

Time frame:
Assessed at end of study; the median (minimum, maximum) time on study for all enrolled participants was 13.9 (0.0, 74.7) months.
Reported as:
Count of participants · Participants
Number of Participants With Anti-denosumab Binding Antibodies
ParticipantsDenosumab
Number of Participants With Anti-denosumab Binding Antibodies0

Adverse events

Collected over From first dose of denosumab in Study 20110113 to end of study. Median (minimum, maximum) time on study was 13.93 (0.0, 74.7) months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Denosumab18/128 (14.1%)45/128 (35.2%)66/128 (51.6%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventDenosumab
Osteonecrosis of jawMusculoskeletal and connective tissue disorders7/128
PneumoniaInfections and infestations4/128
AnaemiaBlood and lymphatic system disorders3/128
OsteomyelitisInfections and infestations3/128
Pleural effusionRespiratory, thoracic and mediastinal disorders3/128
Febrile neutropeniaBlood and lymphatic system disorders2/128
Abdominal painGastrointestinal disorders2/128
AscitesGastrointestinal disorders2/128
Intestinal obstructionGastrointestinal disorders2/128
VomitingGastrointestinal disorders2/128
Most frequent other events
Showing 10 of 14
Most frequent other events
EventDenosumab
Back painMusculoskeletal and connective tissue disorders16/128
NauseaGastrointestinal disorders15/128
AstheniaGeneral disorders15/128
ArthralgiaMusculoskeletal and connective tissue disorders15/128
Decreased appetiteMetabolism and nutrition disorders14/128
Pain in extremityMusculoskeletal and connective tissue disorders13/128
FatigueGeneral disorders12/128
DiarrhoeaGastrointestinal disorders11/128
VomitingGastrointestinal disorders11/128
Abdominal painGastrointestinal disorders9/128

Baseline characteristics

Age, Continuous
Age, Continuous(years)Denosumab
Mean65.74 ± 11.48
Age, Customized
Age, Customized(Participants)Denosumab
18 - 64 years60
65 - 74 years36
75 - 84 years28
≥ 85 years5
Sex: Female, Male
Sex: Female, Male(Participants)Denosumab
Female97
Male32
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Denosumab
Hispanic or Latino28
Not Hispanic or Latino101
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Denosumab
White103
Asian15
Black or African American6
Other4
Unknown1
08

Study locations

64 sites
  • Research Site
    Capital Federal, Buenos Aires C1426ANZ, Argentina
  • Research Site
    Quilmes, Buenos Aires B1878GEG, Argentina
  • Research Site
    Cordoba, Córdoba X5016KEH, Argentina
  • Research Site
    Rosario, Santa Fe S2000PBJ, Argentina
  • Research Site
    Wien, 1090, Austria
  • Research Site
    Namur, 5000, Belgium
  • Research Site
    Porto Alegre, Rio Grande Do Sul 90035-003, Brazil
  • Research Site
    Porto Alegre, Rio Grande Do Sul 90610-000, Brazil
  • Research Site
    Santo Andre, São Paulo 09060-650, Brazil
  • Research Site
    Sao Paulo, São Paulo 01221-020, Brazil
  • Research Site
    Sao Paulo, São Paulo 01509-900, Brazil
  • Research Site
    Sao Paulo, São Paulo 04262-000, Brazil
  • Research Site
    Sorocaba, São Paulo 18030-200, Brazil
  • Research Site
    Rio de Janeiro, 20551-030, Brazil
  • Research Site
    Rio de Janeiro, 22640-000, Brazil
  • Research Site
    São Paulo, 01209-000, Brazil
  • Research Site
    Kromeriz, 767 55, Czechia
  • Research Site
    Olomouc, 775 20, Czechia
  • Research Site
    Praha 1, 110 00, Czechia
  • Research Site
    Praha 4, 140 00, Czechia
  • Research Site
    Praha 4, 140 44, Czechia
  • Research Site
    Praha 5, 150 06, Czechia
  • Research Site
    Saint Cloud, 92210, France
  • Research Site
    Debrecen, 4012, Hungary
  • Research Site
    Dombovar, 7200, Hungary
  • Research Site
    Haifa, 31096, Israel
  • Research Site
    Rehovot, 76100, Israel
  • Research Site
    Tel-Aviv, 64239, Israel
  • Research Site
    Zerifin, 70300, Israel
  • Research Site
    Meldola (FC), 47014, Italy
  • Research Site
    Sora, 03039, Italy
  • Research Site
    Kure-shi, Hiroshima 737-0023, Japan
  • Research Site
    Kagoshima-shi, Kagoshima 892-0833, Japan
  • Research Site
    Isehara-shi, Kanagawa 259-1193, Japan
  • Research Site
    Osaka-shi, Osaka 540-0006, Japan
  • Research Site
    Kitaadachi-gun, Saitama 362-0806, Japan
  • Research Site
    Chuo-ku, Tokyo 104-0045, Japan
  • Research Site
    Tokyo, 135-8550, Japan
  • Research Site
    Daugavpils, 5417, Latvia
  • Research Site
    Riga, 1079, Latvia
  • Research Site
    Kaunas, 50009, Lithuania
  • Research Site
    Vilnius, 08660, Lithuania
  • Research Site
    Panama, Panama
  • Research Site
    Lima, Lima 18, Peru
  • Research Site
    Lima, Lima 27, Peru
  • Research Site
    Bialystok, 15-027, Poland
  • Research Site
    Bydgoszcz, 85-171, Poland
  • Research Site
    Gdansk, 80-952, Poland
  • Research Site
    Lublin, 20-954, Poland
  • Research Site
    Poznan, 61-866, Poland
  • Research Site
    Warszawa, 00-631, Poland
  • Research Site
    Arkhangelsk, 163045, Russian Federation
  • Research Site
    Chelyabinsk, 454087, Russian Federation
  • Research Site
    Krasnogorsky District, 143423, Russian Federation
  • Research Site
    Moscow, 115478, Russian Federation
  • Research Site
    Obninsk, 249036, Russian Federation
  • Research Site
    Omsk, 644013, Russian Federation
  • Research Site
    St Petersburg, 197089, Russian Federation
  • Research Site
    Pretoria, 0081, South Africa
  • Research Site
    Sevilla, Andalucía 41013, Spain
  • Research Site
    Valencia, Comunidad Valenciana 46009, Spain
  • Research Site
    Madrid, 28034, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Lviv, 79031, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2011 to primary completion in Aug 2018, 80 months.

Results were first posted in Sep 2019, 1 year after primary completion.

Of 119 industry-sponsored phase 3 interventional studies under Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's 80 months is above that.

Counting every sponsor, half of 202 studies reached it within 50 months; a quarter within 33 and three quarters within 84.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2011
First posted
Aug 18, 2011
StartActual
Nov 22, 2011
Primary completionActual
Aug 10, 2018
CompletionActual
Aug 10, 2018
Results first posted
Sep 9, 2019
Last update
Sep 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01419717
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 18, 2011
Start date
Nov 22, 2011
Primary completion
Aug 10, 2018
Completion
Aug 10, 2018
Results posted
Sep 9, 2019
Last update
Sep 24, 2019

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion